Sage Journals: Discover world-class research

Abstract

Background

Tubulointerstitial inflammation (TII) in lupus nephritis is associated with a worse prognosis. Vimentin, a filamental antigen, is commonly targeted by in situ activated B-cells in TII. The prognostic importance of high serum anti-vimentin antibodies (AVAs) in lupus nephritis and their relationship with common lupus autoantibody specificities is unknown. Herein we investigated associations between AVA isotypes, other autoantibodies, and response to mycophenolate mofetil (MMF) in the presence or absence of rituximab.

Methods

The Translational Research Initiative in the Department of Medicine (TRIDOM) cross-sectional cohort of 99 lupus patients was assayed for IgG-, IgA- and IgM- AVAs, lupus-associated and rheumatoid arthritis-associated antibodies, and hierarchically clustered. Serum from baseline, 26 and 52 weeks from 132 Lupus Nephritis Assessment with Rituximab (LUNAR) trial enrolled lupus nephritis patients was also analysed and correlated with renal function up to week 78.

Results

In TRIDOM, AVAs, especially IgM AVAs, clustered with IgG anti-dsDNA and away from anti-Sm and -RNP and rheumatoid arthritis-associated antibodies. In LUNAR at baseline, AVAs correlated weakly with anti-dsDNA and more strongly with anticardiolipin titers. Regardless of treatment, IgG-, but not IgM- or IgA-, AVAs were higher at week 52 than at baseline. In contrast, anti-dsDNA titers declined, regardless of therapeutic regime. High IgG AVA titers at entry predicted less response to therapy.

Conclusion

AVAs, especially IgG AVAs, are unique in distribution and response to therapy compared with other commonly measured autoantibody specificities. Furthermore, high-titer IgG AVAs identify lupus nephritis patients resistant to conventional therapies. These data suggest that AVAs represent an independent class of prognostic autoantibodies.

Keywords

Vimentin autoantibodies systemic lupus erythematosus lupus nephritis prognosis

Get full access to this article

View all access options for this article.

References

Edelbauer

Jungraithmayr

Zimmerhackl

LB.

Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: Case report. Pediatr Nephrol 2005; 20: 811–813.

Fra

Avanzi

Bartoli

Remission of refractory lupus nephritis with a protocol including rituximab. Lupus 2003; 12: 783–787.

Van Vollenhoven

Gunnarsson I, Welin-Henriksson E, et al. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol 2004; 33: 423–427.

Condon

Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013; 72: 1280–1286.

Gracia-Tello

Ezeonyeji

Isenberg

The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness. Lupus Sci Med 2017; 4: e000182.

Bertsias

Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771–1782.

Hahn

McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797–808.

Rovin

Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215–1226.

Cambridge

Leandro MJ, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: Effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006; 54: 3612–3622.

10.

Lal

Su Z, Holweg CT, et al. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment. Arthritis Rheum 2011; 63: 3681–3691.

11.

Sellam

Hendel-Chavez H, Rouanet S, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six-month, national, multicenter, open-label study. Arthritis Rheum 2011; 63: 933–938.

12.

Hsieh

Chang A, Brandt D, Guttikonda R, Utset TO, Clark MR. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res (Hoboken) 2011; 63: 865–874.

13.

Pamfil

Makowska Z, De Groof A. Intrarenal activation of adaptive immune effectors is associated with tubular damage and impaired renal function in lupus nephritis. Ann Rheum Dis 2018; 77: 1782--1789.

14.

Chang

Henderson SG, Brandt D, et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol 2011; 186: 1849–1860.

15.

Wang J, Perper S, et al. Bcl-2 as a Therapeutic Target in Human Tubulointerstitial Inflammation. Arthritis Rheumatol 2016; 68: 2740–2751.

16.

Liarski

Kaverina N, Chang A, et al. Cell distance mapping identifies functional T follicular helper cells in inflamed human renal tissue. Sci Transl Med 2014; 6: 230ra46.

17.

Liarski

Sibley A, van Panhuys N, et al. Quantifying in situ adaptive immune cell cognate interactions in humans. Nat Immunol 2019; 20: 503–513.

18.

Kinloch

Chang A, Ko K, et al. Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis. Arthritis Rheumatol 2014; 66: 3359–3370.

19.

Huet

Bagot M, Loyaux D, et al. SC5 mAb represents a unique tool for the detection of extracellular vimentin as a specific marker of Sezary cells. J Immunol 2006; 176: 652–659.

20.

Mor-Vaknin

Punturieri A, Sitwala K, Markovitz DM. Vimentin is secreted by activated macrophages. Nat Cell Biol 2003; 5: 59–63.

21.

Zeisberg

Neilson

EG.

Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009; 119: 1429–1437.

22.

Teshigawara

Kuboyama T, Shigyo M, et al. A novel compound, denosomin, ameliorates spinal cord injury via axonal growth associated with astrocyte-secreted vimentin. Br J Pharmacol 2013; 168: 903–919.

23.

deWaal RM, Mor-Vaknin N, Hibbard C, Markovitz DM, Kahn ML. The endothelial cell-specific antibody PAL-E identifies a secreted form of vimentin in the blood vasculature. Mol Cell Biol 2004; 24: 9198–9206.

24.

Tilleman

Van Steendam K, Cantaert T, De Keyser F, Elewaut D, Deforce D. Synovial detection and autoantibody reactivity of processed citrullinated isoforms of vimentin in inflammatory arthritides. Rheumatology (Oxford) 2008; 47: 597–604.

25.

Kinloch

Kaiser Y, Wolfgeher D, et al.

In situ humoral immunity to vimentin in HLA-DRB1*03(+) patients with pulmonary sarcoidosis.

Front Immunol 2018; 9: 1516.

26.

Didangelos

Puglia M, Iberl M, Sanchez-Bellot C, Roschitzki B. Bradbury EJ. High-throughput proteomics reveal alarmins as amplifiers of tissue pathology and inflammation after spinal cord injury. Sci Rep 2016; 6: 21607.

27.

Tan

Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

28.

Cha

Qin H, Kannan S, et al. Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen. J Immunol 2013; 190: 4887–4898.

29.

Galili

dendextend: An R package for visualizing, adjusting and comparing trees of hierarchical clustering. Bioinformatics 2015; 31: 3718–3720.

30.

Eils R, Schlesner M, Eils

Schlesner

Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 2016. 32: 2847–2849.

31.

Egeland

Lea T, Saari G, Mellbye OJ, Natvig JB. Quantitation of cells secreting rheumatoid factor of IgG, IgA, and IgM class after elution from rheumatoid synovial tissue. Arthritis Rheum 1982; 25: 1445–1450.

32.

Hoffman

Peene I, Meheus L, et al. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis 2004; 63: 1155–1158.

33.

Reddy

Cambridge, G, Isenberg, D, Glennie, MJ, Cragg, MS, Leandro, M. Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheumatol 2015; 67: 2046–2055.

34.

Traub

Vorgias

CE.

Involvement of the N-terminal polypeptide of vimentin in the formation of intermediate filaments. J Cell Sci 1983; 63: 43–67.

35.

Ahrens

Zelenay S, Sancho D, et al. F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity 2012; 36: 635–645.

36.

Zhang

Czabotar PE, Policheni AN, et al. The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. Immunity 2012; 36: 646–657.

37.

Thiagarajan

Yakubenko VP, Elsori DH, et al. Vimentin is an endogenous ligand for the pattern recognition receptor Dectin-1. Cardiovasc Res 2013; 99: 494–504.

38.

Ghosh

Ahrens WA, Phatak SU, Hwang S, Schrum LW, Bonkovsky HL. Association of filamin A and vimentin with hepatitis C virus proteins in infected human hepatocytes. J Viral Hepat 2011; 18: e568–e577.

39.

Bang

Egerer K, Gauliard et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007; 56: 2503–2511.

40.

Carter

Shenton BK, Jaques B, et al. Vimentin antibodies: A non-HLA antibody as a potential risk factor in renal transplantation. Transplant Proc 2005; 37: 654–657.

41.

Jurcevic

Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001; 71: 886–892.

42.

Wheeler

Collins A, Dunn MJ, Crisp SJ, Yacoub MH, Rose ML. Characterization of endothelial antigens associated with transplant-associated coronary artery disease. J Heart Lung Transplant 1995; 14: S188–S197.

43.

Kurki

Miettinen A, Salaspuro M, Virtanen I, Stenman S. Cytoskeleton antibodies in chronic active hepatitis, primary biliary cirrhosis, and alcoholic liver disease. Hepatology 1983; 3: 297–302.

44.

Surolia R, Li H, et al. Autoimmunity to vimentin is associated with outcomes of patients with idiopathic pulmonary fibrosis. J Immunol 2017; 199: 1596–1605.

45.

Brown

Pedersen J, Underwood JR, Gust I, Toh BH. Autoantibodies to intermediate filaments in acute viral hepatitis A, B and non-A, non-B are directed against vimentin. J Clin Lab Immunol 1986; 19: 1–4.

46.

Kaneko

Nimmerjahn

Ravetch

JV.

Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006. 313: 670–673.

47.

Wahlstrom

Dengjel J, Winqvist O, et al. Autoimmune T cell responses to antigenic peptides presented by bronchoalveolar lavage cell HLA-DR molecules in sarcoidosis. Clin Immunol 2009; 133: 353–363.

48.

Graham

Ortmann W, Rodine P, et al. Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE. Eur J Hum Genet 2007; 15: 823–830.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

1.09 MB